Ticagrelor

Kang Y, et al. Biomedicine & Pharmacotherapy, 2025, 192, 118695.

This study investigated the effect of Ticagrelor on tumor-associated macrophages (TAMs) to enhance immunotherapy in pancreatic ductal adenocarcinoma (PDAC). Researchers established co-cultures of PDAC cells and TAMs, applying Ticagrelor to block the macrophage P2Y12 receptor, combined with cemiplimab or BMS-1 to inhibit PD-1/PD-L1 interactions. Functional assays demonstrated that Ticagrelor treatment enhanced TAM phagocytic activity and suppressed TAM-induced cancer cell proliferation and migration. Mechanistically, the combination therapy reduced TGF-β1 secretion from TAMs and inhibited Smad2 phosphorylation in pancreatic cancer cells, indicating downregulation of the TGF-β1/Smad2 pathway.

Dave S, et al. European Journal of Pharmacology, 2025, 1003, 177955.

A meta-analysis evaluated Ticagrelor's antiplatelet efficacy and safety in acute coronary syndrome (ACS) and post-myocardial infarction (post-MI) patients undergoing percutaneous coronary intervention (PCI). Eight randomized controlled trials compared Ticagrelor with clopidogrel. Experimental endpoints included stent thrombosis, revascularization, major adverse cardiovascular events (MACE), and mortality. Ticagrelor significantly reduced stent thrombosis (OR 0.71) and demonstrated a clinically meaningful reduction in mortality (OR 0.85), while trends in revascularization and MACE were not statistically significant due to heterogeneity. These findings illustrate the experimental application of Ticagrelor as a potent P2Y12 receptor antagonist in clinical settings, effectively inhibiting platelet aggregation and reducing thrombotic complications, supporting its use as a preferred antiplatelet therapy in high-risk cardiovascular patients.